OncoMatch/Clinical Trials/NCT05528887
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Is NCT05528887 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Autologous CAR-T cells and Fludarabine for relapsed/refractory hematological malignancies.
Treatment: Autologous CAR-T cells · Fludarabine · Cyclophosphamide — The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard therapy
refractory to, or relapsing after standard therapy
Lab requirements
Kidney function
Serum creatinine (Cr) ≤ 2 × upper limit of normal (ULN)
Liver function
Serum bilirubin ≤ 35 μmol/L; AST/ALT < 2
Cardiac function
Brain natriuretic peptide (BNP)<80 pg/mL; LVEF < 50% [excluded]; Class III or IV heart failure as defined by NYHA [excluded]
Adequate organ functions: Serum bilirubin ≤ 35 μmol/L; AST/ALT < 2; Serum creatinine (Cr) ≤ 2 × ULN; BNP<80 pg/mL. History of cardiac diseases: LVEF < 50%; Class III or IV heart failure as defined by NYHA
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05528887 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify